Meet the Decision-Makers in Oligonucleotide Analytical Development & CMC
Join a highly curated audience of global biotech, mid-sized pharma, and cutting-edge oligonucleotide specialists advancing analytical development and CMC strategies. Attending companies span innovative biotech disruptors, established pharmaceutical leaders, CDMOs, and key technology providers - collectively shaping the future of oligonucleotide therapeutics across discovery, scale-up, and commercialisation.
You will be in the room with Heads of Analytical Development, Directors of CMC, VPs of Technical Operations, and Senior Leaders across Process Development, Manufacturing, and Regulatory Affairs. The attendee profile reflects a clear pattern: decision-makers responsible for pipeline progression, technology adoption, and manufacturing strategy, supported by highly specialised technical experts driving execution.
What makes this audience uniquely powerful is its cross-functional depth. Organisations are bringing together stakeholders from analytical development, CMC, and manufacturing to solve shared bottlenecks - from impurity characterization and method validation to scale-up challenges and regulatory readiness. If you are not in the room, you are missing direct access to the teams actively defining how oligonucleotide therapeutics are developed, validated, and brought to market.
How Teams are Maximizing ROI at the Meeting
A clear trend emerging from this year’s attendee base: companies are not sending individuals - they are sending teams.
Leading organisations are already securing multiple passes to ensure full coverage of analytical, CMC, and manufacturing discussions. Confirmed examples include:
Alnylam Pharmaceuticals (3), Biogen (3), Eli Lilly (3), Souffle Therapeutics (3), Amgen (2), Boehringer Ingelheim (2), Asymchem Laboratories (2), City Therapeutics (2)
This reflects how critical cross-functional alignment has become in oligonucleotide development - particularly as programmes move from early-stage analytical challenges into late-stage CMC and commercial readiness. With increasing technical complexity and regulatory scrutiny, organisations recognise that no single role can capture the full value of the agenda. Teams are required to fully capitalize on the insights, discussions, and benchmarking opportunities available.
Align cross-functional teams faster
Ensure internal stakeholders leave with a unified and actionable strategy
Maximize ROI from attendance
Capture more insights, contacts, and practical learnings across the full event
Bring back actionable insights
Accelerate decision-making across your pipeline or platform
Benchmark against peers
Gain broader perspectives when engaging with other senior decision-makers
All Attending Companies
Explore the Agenda
Dive into cutting-edge Oligonucleotide Analytical Development & CMC strategies that will become your blueprint to high quality, safe, and cost-effective Oligo production across all modalities.
Partner With Us
Showcase your technologies and services to decision-makers actively seeking the tools to advance next-generation Oligonucleotide therapies.
Join Biopharma Experts
Be part of the only forum uniting leading pharma, biotech, academia, and regulatory experts.